You can buy or sell SAVA and other stocks, options, and ETFs commission-free!
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. The listed name for SAVA is Cassava Sciences, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 25, Pre-Market